Dominique J. Barbeau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Dominique J. Barbeau has a total of 112 co-authors. Here are the top co-authors by number of shared publications:
- Anita K. McElroy
Division of Infectious Diseases, Department of Pediatrics, University of Pittsburgh
14 shared publications - William Paul Duprex
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
5 shared publications Joshua D. Doyle
Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, USA
4 shared publications- Haley N. Cartwright
Affiliation University of Pittsburgh, School of Medicine, Department of Pediatrics, Division of Pediatric Infectious Disease, and Center for Vaccine Research, Pittsburgh, Pennsylvania, United States of America
3 shared publications Alejandro Hoberman
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, USA
2 shared publications- Amy Lynn Hartman
Center for Vaccine Research, University of Pittsburgh School of Medicine
2 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (11)
Multiplexed Fc array assays reveal the influence of TLR3 on the Th1-biased humoral response induced in mice following live-attenuated RVFV vaccination
Rift Valley fever virus (RVFV) can cause severe disease in humans and livestock. Several vaccine candidates are immunogenic and protective in pre-clinical animal models. Reported measurements of humoral immunity following vaccination typically assess antigen-specific activity, such as virus binding or neutralization, but do not consider the role of the Fc region. To address this knowledge gap, multiplexed Fc array assays were developed to characterize the Fc profile of antigen-specific antibodies following RVFV vaccination. The RVFV nucleocapsid protein (N) and glycoproteins (Gn/Gc) were conjugated to magnetic microspheres, and monoclonal antibodies were used to optimize assay conditions. Sera from vaccinated mice were incubated with the conjugated microspheres to capture antigen-specific antibodies, and then various detection reagents were used to measure the isotype of the antibodies and their ability to bind Fc receptors (FcRs) or complement (C1q). Two studies involving mice vaccinated with live-attenuated RVFV ΔNSsΔNSm or ΔNSs were used to demonstrate the utility of these assays. In WT C57BL/6 mice, both ΔNSsΔNSm and ΔNSs induced a high magnitude of IgG2c antibodies, indicative of a Th1-biased response; these antibodies also bound the four murine FcRs and C1q. However, following ΔNSs infection of a panel of innate immune knockout (KO) mice, several strains of KO mice, especially TLR3 KO, exhibited a reduced magnitude of IgG2c antibodies, demonstrating the impact of innate immunity on the Th1-biased response. Overall, the multiplexed Fc array assays performed as expected and can be applied to other RVFV vaccine platforms in the future to help inform rational vaccine design. IMPORTANCE: There are currently no approved vaccines to prevent RVFV infection in humans. While some vaccine candidates exist, such as the live-attenuated ΔNSsΔNSm vaccine, most immunogenicity studies do not consider the contribution of the Fc region to antibody quality. In this study, multiplexed Fc array assays were developed to assess the Fc profile of antigen-specific antibodies following RVFV vaccination. These assays proved to be useful in identifying a Th1-biased response induced by RVFV ΔNSsΔNSm and ΔNSs and in identifying the contribution of innate immunity to this response. These assays can be applied to other RVFV vaccine platforms, such as mRNA and protein vaccines, to fully characterize the quality of an antibody response following vaccination.
- 17 November 2026
- Published by American Society for Microbiology in Journal of Virology
- Vol. 100 (11)
Open AccessMultiplexed Fc array assays reveal the influence of TLR3 on the Th1-biased humoral response induced in mice following live-attenuated RVFV vaccination
Rift Valley fever virus (RVFV) can cause severe disease in humans and livestock. Several vaccine candidates are immunogenic and protective in pre-clinical animal models. Reported measurements of humoral immunity following vaccination typically assess antigen-specific activity, such as virus binding or neutralization, but do not consider the role of the Fc region. To address this knowledge gap, multiplexed Fc array assays were developed to characterize the Fc profile of antigen-specific antibodies following RVFV vaccination. The RVFV nucleocapsid protein (N) and glycoproteins (Gn/Gc) were conjugated to magnetic microspheres, and monoclonal antibodies were used to optimize assay conditions. Sera from vaccinated mice were incubated with the conjugated microspheres to capture antigen-specific antibodies, and then various detection reagents were used to measure the isotype of the antibodies and their ability to bind Fc receptors (FcRs) or complement (C1q). Two studies involving mice vaccinated with live-attenuated RVFV ΔNSsΔNSm or ΔNSs were used to demonstrate the utility of these assays. In WT C57BL/6 mice, both ΔNSsΔNSm and ΔNSs induced a high magnitude of IgG2c antibodies, indicative of a Th1-biased response; these antibodies also bound the four murine FcRs and C1q. However, following ΔNSs infection of a panel of innate immune knockout (KO) mice, several strains of KO mice, especially TLR3 KO, exhibited a reduced magnitude of IgG2c antibodies, demonstrating the impact of innate immunity on the Th1-biased response. Overall, the multiplexed Fc array assays performed as expected and can be applied to other RVFV vaccine platforms in the future to help inform rational vaccine design. IMPORTANCE: There are currently no approved vaccines to prevent RVFV infection in humans. While some vaccine candidates exist, such as the live-attenuated ΔNSsΔNSm vaccine, most immunogenicity studies do not consider the contribution of the Fc region to antibody quality. In this study, multiplexed Fc array assays were developed to assess the Fc profile of antigen-specific antibodies following RVFV vaccination. These assays proved to be useful in identifying a Th1-biased response induced by RVFV ΔNSsΔNSm and ΔNSs and in identifying the contribution of innate immunity to this response. These assays can be applied to other RVFV vaccine platforms, such as mRNA and protein vaccines, to fully characterize the quality of an antibody response following vaccination.
- Open Access
- 15 May 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e812-e822
Live-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice
Background: Rift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but several candidates are at the clinical trial, stage including DDVax™, a preparation of live-attenuated RVFV lacking the nonstructural proteins NSs and NSm (ΔNSsΔNSm). Multiple preclinical studies have shown that ΔNSsΔNSm is safe and immunogenic. Methods: The longitudinal study described in this manuscript examined the additional features of duration, sex, and dose in immunogenicity and protection provided by ΔNSsΔNSm. Female and male 8-week-old C57BL/6 mice were vaccinated with either a low or high dose of ΔNSsΔNSm and humoral (via neutralization assay and enzyme-linked immunosorbent assay) and cellular immunity (enzyme-linked immunospot and flow cytometry) were assessed over a period of 6 months. A subset of animals was challenged with a lethal dose of wild-type RVFV 6 months postvaccination. Results: All vaccinated animals were protected against lethal RVF disease 6 months postvaccination independent of dose or sex. Humoral immunity in the form of RVFV-specific neutralizing and binding antibodies decreased over time but remained detectable at the end of the study. The RVFV-specific CD4+ T cells also decreased by 6 months postvaccination. In contrast, virus-specific polyfunctional CD8+ T cells persisted at comparable levels throughout the study. Conclusions: This work demonstrates that a single low-dose ΔNSsΔNSm vaccine elicits a durable humoral and cellular immune response that persists over months and protects C57BL/6 mice against lethal RVF disease.
- 15 May 2026
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 234 (4) , e812-e822
Open AccessLive-Attenuated Rift Valley Fever Virus Vaccination Leads to Durable, Protective Immunity Independent of Sex in C57BL/6 Mice
Background: Rift Valley fever virus (RVFV) is a zoonotic arbovirus endemic to Africa and the Arabian Peninsula that can cause disease in humans and livestock. There are currently no licensed vaccines for human use, but several candidates are at the clinical trial, stage including DDVax™, a preparation of live-attenuated RVFV lacking the nonstructural proteins NSs and NSm (ΔNSsΔNSm). Multiple preclinical studies have shown that ΔNSsΔNSm is safe and immunogenic. Methods: The longitudinal study described in this manuscript examined the additional features of duration, sex, and dose in immunogenicity and protection provided by ΔNSsΔNSm. Female and male 8-week-old C57BL/6 mice were vaccinated with either a low or high dose of ΔNSsΔNSm and humoral (via neutralization assay and enzyme-linked immunosorbent assay) and cellular immunity (enzyme-linked immunospot and flow cytometry) were assessed over a period of 6 months. A subset of animals was challenged with a lethal dose of wild-type RVFV 6 months postvaccination. Results: All vaccinated animals were protected against lethal RVF disease 6 months postvaccination independent of dose or sex. Humoral immunity in the form of RVFV-specific neutralizing and binding antibodies decreased over time but remained detectable at the end of the study. The RVFV-specific CD4+ T cells also decreased by 6 months postvaccination. In contrast, virus-specific polyfunctional CD8+ T cells persisted at comparable levels throughout the study. Conclusions: This work demonstrates that a single low-dose ΔNSsΔNSm vaccine elicits a durable humoral and cellular immune response that persists over months and protects C57BL/6 mice against lethal RVF disease.
- Open Access
- 23 October 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (10) , e0126125
Limiting viral replication in hematopoietic cells delays Rift Valley fever virus disease progression in C57BL/6 mice
Rift Valley fever virus (RVFV) causes mild to severe disease in livestock and humans. It was first identified in 1931 during an epizootic in Kenya and has spread across Africa and into the Middle East. Hematopoietic cells are one of the major targets of RVFV in vivo ; however, their contribution to RVFV pathogenesis remains poorly understood. To address this, we generated a recombinant miRNA-targeted virus, RVFVmiR-142, to limit viral replication in hematopoietic cells and evaluated the consequences on RVFV disease manifestations in C57BL/6 mice. MicroRNAs are evolutionarily conserved non-coding RNAs that regulate mRNA expression. RVFVmiR-142 includes an insertion of four repeated sequences targeted by hematopoietic-specific miRNA-142. RVFVmiR-MM, which contains four repeats of sequences that are not targets of any known miRNA, was generated as a control. RVFVmiR-142 showed restricted replication in vitro compared to RVFVmiR-MM. C57BL/6 mice infected with 2 TCID 50 of RVFVmiR-142 had delayed disease progression vs RVFVmiR-MM-infected mice, the phenotype of which was overcome by higher infection doses. The difference in disease progression at low dose was eliminated in MiR-142 KO mice, confirming the specificity of the phenotype. A timed euthanasia study showed delayed viral replication of RVFVmiR-142 compared to RVFVmiR-MM in infected mice, most notably in tissues largely composed of hematopoietic cells. Furthermore, control of RVFVmiR-142 replication in the popliteal lymph nodes correlated with an increased type I IFN response, which was lacking in the liver tissue where RVFVmiR-142 replication continued to increase. These data suggest that RVFV replication in hematopoietic cells contributes to viral amplification and/or spread. IMPORTANCE: RVFV is a segmented, single-stranded, negative-sense RNA virus vectored by diverse genera of mosquitoes and can infect a variety of wild animals, domesticated livestock, and humans. Despite the increase in both the range and frequency of RVFV outbreaks over the years, there is currently no vaccine or treatment available for human use against RVFV. Mononuclear phagocytic cells (MPCs) are one of the major targets of RVFV in vivo ; however, the contribution of RVFV replication in these cells to its pathogenesis has not been well characterized. In this study, we generated a recombinant miRNA-targeted virus with restricted replication in hematopoietic cells and examined its pathogenesis in C57BL/6 mice. This study demonstrates that hematopoietic cell infection contributes to viral pathogenesis by augmenting viral amplification and/or spread.
- 23 October 2025
- Published by American Society for Microbiology in Journal of Virology
- Vol. 99 (10) , e0126125
Open AccessLimiting viral replication in hematopoietic cells delays Rift Valley fever virus disease progression in C57BL/6 mice
Rift Valley fever virus (RVFV) causes mild to severe disease in livestock and humans. It was first identified in 1931 during an epizootic in Kenya and has spread across Africa and into the Middle East. Hematopoietic cells are one of the major targets of RVFV in vivo ; however, their contribution to RVFV pathogenesis remains poorly understood. To address this, we generated a recombinant miRNA-targeted virus, RVFVmiR-142, to limit viral replication in hematopoietic cells and evaluated the consequences on RVFV disease manifestations in C57BL/6 mice. MicroRNAs are evolutionarily conserved non-coding RNAs that regulate mRNA expression. RVFVmiR-142 includes an insertion of four repeated sequences targeted by hematopoietic-specific miRNA-142. RVFVmiR-MM, which contains four repeats of sequences that are not targets of any known miRNA, was generated as a control. RVFVmiR-142 showed restricted replication in vitro compared to RVFVmiR-MM. C57BL/6 mice infected with 2 TCID 50 of RVFVmiR-142 had delayed disease progression vs RVFVmiR-MM-infected mice, the phenotype of which was overcome by higher infection doses. The difference in disease progression at low dose was eliminated in MiR-142 KO mice, confirming the specificity of the phenotype. A timed euthanasia study showed delayed viral replication of RVFVmiR-142 compared to RVFVmiR-MM in infected mice, most notably in tissues largely composed of hematopoietic cells. Furthermore, control of RVFVmiR-142 replication in the popliteal lymph nodes correlated with an increased type I IFN response, which was lacking in the liver tissue where RVFVmiR-142 replication continued to increase. These data suggest that RVFV replication in hematopoietic cells contributes to viral amplification and/or spread. IMPORTANCE: RVFV is a segmented, single-stranded, negative-sense RNA virus vectored by diverse genera of mosquitoes and can infect a variety of wild animals, domesticated livestock, and humans. Despite the increase in both the range and frequency of RVFV outbreaks over the years, there is currently no vaccine or treatment available for human use against RVFV. Mononuclear phagocytic cells (MPCs) are one of the major targets of RVFV in vivo ; however, the contribution of RVFV replication in these cells to its pathogenesis has not been well characterized. In this study, we generated a recombinant miRNA-targeted virus with restricted replication in hematopoietic cells and examined its pathogenesis in C57BL/6 mice. This study demonstrates that hematopoietic cell infection contributes to viral pathogenesis by augmenting viral amplification and/or spread.
- Open Access
- 20 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0290909
No evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model
Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-dependent enhancement (ADE) of disease as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral/ocular) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7–10 days post-infection. To evaluate the potential for ADE, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2.
- 20 June 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19 (6) , e0290909
Open AccessNo evidence for enhanced disease with human polyclonal SARS-CoV-2 antibody in the ferret model
Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-dependent enhancement (ADE) of disease as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral/ocular) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7–10 days post-infection. To evaluate the potential for ADE, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2.
- Open Access
- 13 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Potential pandemic risk of circulating swine H1N2 influenza viruses
Influenza A viruses in swine have considerable genetic diversity and continue to pose a pandemic threat to humans due to a potential lack of population level immunity. Here we describe a pipeline to characterize and triage influenza viruses for their pandemic risk and examine the pandemic potential of two widespread swine origin viruses. Our analysis reveals that a panel of human sera collected from healthy adults in 2020 has no cross-reactive neutralizing antibodies against a α-H1 clade strain (α-swH1N2) but do against a γ-H1 clade strain. The α-swH1N2 virus replicates efficiently in human airway cultures and exhibits phenotypic signatures similar to the human H1N1 pandemic strain from 2009 (H1N1pdm09). Furthermore, α-swH1N2 is capable of efficient airborne transmission to both naïve ferrets and ferrets with prior seasonal influenza immunity. Ferrets with H1N1pdm09 pre-existing immunity show reduced α-swH1N2 viral shedding and less severe disease signs. Despite this, H1N1pdm09-immune ferrets that became infected via the air can still onward transmit α-swH1N2 with an efficiency of 50%. These results indicate that this α-swH1N2 strain has a higher pandemic potential, but a moderate level of impact since there is reduced replication fitness and pathology in animals with prior immunity.
- 13 June 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-13
Open AccessPotential pandemic risk of circulating swine H1N2 influenza viruses
Influenza A viruses in swine have considerable genetic diversity and continue to pose a pandemic threat to humans due to a potential lack of population level immunity. Here we describe a pipeline to characterize and triage influenza viruses for their pandemic risk and examine the pandemic potential of two widespread swine origin viruses. Our analysis reveals that a panel of human sera collected from healthy adults in 2020 has no cross-reactive neutralizing antibodies against a α-H1 clade strain (α-swH1N2) but do against a γ-H1 clade strain. The α-swH1N2 virus replicates efficiently in human airway cultures and exhibits phenotypic signatures similar to the human H1N1 pandemic strain from 2009 (H1N1pdm09). Furthermore, α-swH1N2 is capable of efficient airborne transmission to both naïve ferrets and ferrets with prior seasonal influenza immunity. Ferrets with H1N1pdm09 pre-existing immunity show reduced α-swH1N2 viral shedding and less severe disease signs. Despite this, H1N1pdm09-immune ferrets that became infected via the air can still onward transmit α-swH1N2 with an efficiency of 50%. These results indicate that this α-swH1N2 strain has a higher pandemic potential, but a moderate level of impact since there is reduced replication fitness and pathology in animals with prior immunity.
- 14 May 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (5) , e0176223
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and is responsible for the largest human pandemic in 100 years. Thirty-four vaccines are currently approved for use worldwide, and approximately 67% of the world population has received a complete primary series of one, yet countries are dealing with new waves of infections, variant viruses continue to emerge, and breakthrough infections are frequent secondary to waning immunity. Here, we evaluate a measles virus (MV)-vectored vaccine expressing a stabilized prefusion SARS-CoV-2 spike (S) protein (MV-ATU3-S2PΔF2A; V591) with demonstrated immunogenicity in mouse models (see companion article [J. Brunet, Z. Choucha, M. Gransagne, H. Tabbal, M.-W. Ku et al., J Virol 98:e01693-23, 2024, https://doi.org/10.1128/jvi.01693-23 ]) in an established African green monkey model of disease. Animals were vaccinated with V591 or the control vaccine (an equivalent MV-vectored vaccine with an irrelevant antigen) intramuscularly using a prime/boost schedule, followed by challenge with an early pandemic isolate of SARS-CoV-2 at 56 days post-vaccination. Pre-challenge, only V591-vaccinated animals developed S-specific antibodies that had virus-neutralizing activity as well as S-specific T cells. Following the challenge, V591-vaccinated animals had lower infectious virus and viral (v) RNA loads in mucosal secretions and stopped shedding virus in these secretions earlier. vRNA loads were lower in these animals in respiratory and gastrointestinal tract tissues at necropsy. This correlated with a lower disease burden in the lungs as quantified by PET/CT at early and late time points post-challenge and by pathological analysis at necropsy. IMPORTANCE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the largest human pandemic in 100 years. Even though vaccines are currently available, countries are dealing with new waves of infections, variant viruses continue to emerge, breakthrough infections are frequent, and vaccine hesitancy persists. This study uses a safe and effective measles vaccine as a platform for vaccination against SARS-CoV-2. The candidate vaccine was used to vaccinate African green monkeys (AGMs). All vaccinated AGMs developed robust antigen-specific immune responses. After challenge, these AGMs produced less virus in mucosal secretions, for a shorter period, and had a reduced disease burden in the lungs compared to control animals. At necropsy, lower levels of viral RNA were detected in tissue samples from vaccinated animals, and the lungs of these animals lacked the histologic hallmarks of SARS-CoV-2 disease observed exclusively in the control AGMs.
- 14 May 2024
- Published by American Society for Microbiology in Journal of Virology
- Vol. 98 (5) , e0176223
A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged at the end of 2019 and is responsible for the largest human pandemic in 100 years. Thirty-four vaccines are currently approved for use worldwide, and approximately 67% of the world population has received a complete primary series of one, yet countries are dealing with new waves of infections, variant viruses continue to emerge, and breakthrough infections are frequent secondary to waning immunity. Here, we evaluate a measles virus (MV)-vectored vaccine expressing a stabilized prefusion SARS-CoV-2 spike (S) protein (MV-ATU3-S2PΔF2A; V591) with demonstrated immunogenicity in mouse models (see companion article [J. Brunet, Z. Choucha, M. Gransagne, H. Tabbal, M.-W. Ku et al., J Virol 98:e01693-23, 2024, https://doi.org/10.1128/jvi.01693-23 ]) in an established African green monkey model of disease. Animals were vaccinated with V591 or the control vaccine (an equivalent MV-vectored vaccine with an irrelevant antigen) intramuscularly using a prime/boost schedule, followed by challenge with an early pandemic isolate of SARS-CoV-2 at 56 days post-vaccination. Pre-challenge, only V591-vaccinated animals developed S-specific antibodies that had virus-neutralizing activity as well as S-specific T cells. Following the challenge, V591-vaccinated animals had lower infectious virus and viral (v) RNA loads in mucosal secretions and stopped shedding virus in these secretions earlier. vRNA loads were lower in these animals in respiratory and gastrointestinal tract tissues at necropsy. This correlated with a lower disease burden in the lungs as quantified by PET/CT at early and late time points post-challenge and by pathological analysis at necropsy. IMPORTANCE: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the largest human pandemic in 100 years. Even though vaccines are currently available, countries are dealing with new waves of infections, variant viruses continue to emerge, breakthrough infections are frequent, and vaccine hesitancy persists. This study uses a safe and effective measles vaccine as a platform for vaccination against SARS-CoV-2. The candidate vaccine was used to vaccinate African green monkeys (AGMs). All vaccinated AGMs developed robust antigen-specific immune responses. After challenge, these AGMs produced less virus in mucosal secretions, for a shorter period, and had a reduced disease burden in the lungs compared to control animals. At necropsy, lower levels of viral RNA were detected in tissue samples from vaccinated animals, and the lungs of these animals lacked the histologic hallmarks of SARS-CoV-2 disease observed exclusively in the control AGMs.
- Open Access
No evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model
Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-enhanced disease (AED) as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7-10 days post-infection. To evaluate the potential for AED, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2.
Open AccessNo evidence for enhanced disease with polyclonal SARS-CoV-2 antibody in the ferret model
Since SARS-CoV-2 emerged in late 2019, it spread from China to the rest of the world. An initial concern was the potential for vaccine- or antibody-enhanced disease (AED) as had been reported with other coronaviruses. To evaluate this, we first developed a ferret model by exposing ferrets to SARS-CoV-2 by either mucosal inoculation (intranasal/oral) or inhalation using a small particle aerosol. Mucosal inoculation caused a mild fever and weight loss that resolved quickly; inoculation via either route resulted in virus shedding detected in the nares, throat, and rectum for 7-10 days post-infection. To evaluate the potential for AED, we then inoculated groups of ferrets intravenously with 0.1, 0.5, or 1 mg/kg doses of a human polyclonal anti-SARS-CoV-2 IgG from hyper-immunized transchromosomic bovines (SAB-185). Twelve hours later, ferrets were challenged by mucosal inoculation with SARS-CoV-2. We found no significant differences in fever, weight loss, or viral shedding after infection between the three antibody groups or the controls. Signs of pathology in the lungs were noted in infected ferrets but no differences were found between control and antibody groups. The results of this study indicate that healthy, young adult ferrets of both sexes are a suitable model of mild COVID-19 and that low doses of specific IgG in SAB-185 are unlikely to enhance the disease caused by SARS-CoV-2.
- Open Access
- 28 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-9
Immune correlates of protection following Rift Valley fever virus vaccination
Rift Valley fever virus (RVFV) is a hemorrhagic fever virus with the potential for significant economic and public health impact. Vaccination with an attenuated strain, DelNSsRVFV, provides protection from an otherwise lethal RVFV challenge, but mechanistic determinants of protection are undefined. In this study, a murine model was used to assess the contributions of humoral and cellular immunity to DelNSsRVFV-mediated protection. Vaccinated mice depleted of T cells were protected against subsequent challenge, and passive transfer of immune serum from vaccinated animals to naïve animals was also protective, demonstrating that T cells were dispensable in the presence of humoral immunity and that humoral immunity alone was sufficient. Animals depleted of B cells and then vaccinated were protected against challenge. Total splenocytes, but not T cells alone, B cells alone, or B + T cells harvested from vaccinated animals and then transferred to naïve animals were sufficient to confer protection, suggesting that multiple cellular interactions were required for effective cellular immunity. Together, these data indicate that humoral immunity is sufficient to confer vaccine-mediated protection and suggests that cellular immunity plays a role in protection that requires the interaction of various cellular components.
- 28 October 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-9
Open AccessImmune correlates of protection following Rift Valley fever virus vaccination
Rift Valley fever virus (RVFV) is a hemorrhagic fever virus with the potential for significant economic and public health impact. Vaccination with an attenuated strain, DelNSsRVFV, provides protection from an otherwise lethal RVFV challenge, but mechanistic determinants of protection are undefined. In this study, a murine model was used to assess the contributions of humoral and cellular immunity to DelNSsRVFV-mediated protection. Vaccinated mice depleted of T cells were protected against subsequent challenge, and passive transfer of immune serum from vaccinated animals to naïve animals was also protective, demonstrating that T cells were dispensable in the presence of humoral immunity and that humoral immunity alone was sufficient. Animals depleted of B cells and then vaccinated were protected against challenge. Total splenocytes, but not T cells alone, B cells alone, or B + T cells harvested from vaccinated animals and then transferred to naïve animals were sufficient to confer protection, suggesting that multiple cellular interactions were required for effective cellular immunity. Together, these data indicate that humoral immunity is sufficient to confer vaccine-mediated protection and suggests that cellular immunity plays a role in protection that requires the interaction of various cellular components.
- Open Access
- 6 July 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-6
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the three vaccines. In this observational cohort study, immune responses were evaluated using a SARS-CoV-2 spike protein receptor-binding domain ELISA, SARS-CoV-2 virus neutralization assays and an IFN- γ ELISPOT assay at various times over six months following initial vaccination. mRNA-based vaccines elicited higher magnitude humoral responses than Ad26.COV2.S; mRNA-1273 elicited the most durable humoral response, and all humoral responses waned over time. Neutralizing antibodies against the Delta variant were of lower magnitude than the wild-type strain for all three vaccines. mRNA-1273 initially elicited the greatest magnitude of T cell response, but this declined by 6 months. Declining immunity over time supports the use of booster dosing, especially in the setting of emerging variants.
- 6 July 2022
- Published by Springer Nature in npj Vaccines
- Vol. 7 (1) , 1-6
Open AccessComparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
SARS-CoV-2 vaccines BNT162b2, mRNA-1273, and Ad26.COV2.S received emergency use authorization by the U.S. Food and Drug Administration in 2020/2021. Individuals being vaccinated were invited to participate in a prospective longitudinal comparative study of immune responses elicited by the three vaccines. In this observational cohort study, immune responses were evaluated using a SARS-CoV-2 spike protein receptor-binding domain ELISA, SARS-CoV-2 virus neutralization assays and an IFN- γ ELISPOT assay at various times over six months following initial vaccination. mRNA-based vaccines elicited higher magnitude humoral responses than Ad26.COV2.S; mRNA-1273 elicited the most durable humoral response, and all humoral responses waned over time. Neutralizing antibodies against the Delta variant were of lower magnitude than the wild-type strain for all three vaccines. mRNA-1273 initially elicited the greatest magnitude of T cell response, but this declined by 6 months. Declining immunity over time supports the use of booster dosing, especially in the setting of emerging variants.
- Open Access
- 23 November 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2414
A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the recent use of these phages therapeutically, including by intravenous administration, suggests an excellent safety profile, although efficacy can be restricted by neutralizing antibodies. We describe here the potent immunogenicity of mycobacteriophage Bxb1, and Bxb1 recombinants displaying SARS-CoV-2 Spike protein antigens.
- 23 November 2021
- Published by MDPI AG in Microorganisms
- Vol. 9 (12) , 2414
Open AccessA Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display
The explosion of SARS-CoV-2 infections in 2020 prompted a flurry of activity in vaccine development and exploration of various vaccine platforms, some well-established and some new. Phage-based vaccines were described previously, and we explored the possibility of using mycobacteriophages as a platform for displaying antigens of SARS-CoV-2 or other infectious agents. The potential advantages of using mycobacteriophages are that a large and diverse variety of them have been described and genomically characterized, engineering tools are available, and there is the capacity to display up to 700 antigen copies on a single particle approximately 100 nm in size. The phage body may itself be a good adjuvant, and the phages can be propagated easily, cheaply, and to high purity. Furthermore, the recent use of these phages therapeutically, including by intravenous administration, suggests an excellent safety profile, although efficacy can be restricted by neutralizing antibodies. We describe here the potent immunogenicity of mycobacteriophage Bxb1, and Bxb1 recombinants displaying SARS-CoV-2 Spike protein antigens.